Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients

被引:18
作者
Blandizzi, Corrado [1 ]
Tuccori, Marco [1 ]
Colucci, Rocchina [1 ]
Gori, Giovanni [1 ]
Fornai, Matteo [1 ]
Antonioli, Luca [1 ]
Ghisu, Narcisa [1 ]
Del Tacca, Mario [1 ]
机构
[1] Univ Pisa, Dipartimento Med Interna, Div Farmacol & Chemioterapia, I-56126 Pisa, Italy
关键词
D O I
10.2165/00002512-200825030-00003
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
NSAIDs are widely prescribed for the treatment of pain, inflammation and rheumatic disorders, but their use is associated with adverse gastrointestinal effects, ranging from dyspeptic symptoms and peptic ulcers to more serious complications. Elderly patients are at high risk of experiencing NSAID-induced gastrointestinal tract injury and should be considered candidates for prophylactic pharmacological therapy. In studies conducted in adult patients, proton pump inhibitors (PPIs) such as esomeprazole have been shown to prevent or reduce NSAID-induced gastrointestinal injury. The beneficial effects of esomeprazole can be ascribed largely to its ability to maintain sustained inhibition of gastric acid secretion, although there is evidence to suggest that pharmacodynamic properties unrelated to acid inhibition may also contribute to the gastroprotective effects of this agent. Although there are limited data on the use of esomeprazole specifically in elderly patient populations, studies of patients at high risk of NSAID-induced gastrointestinal toxicity because of advanced age indicate that this PPI is both effective and well tolerated when administered in conjunction with NSAIDs. Thus, esomeprazole can be regarded as a useful option for prophylactic therapy in elderly patients receiving long-term NSAID therapy.
引用
收藏
页码:197 / 208
页数:12
相关论文
共 91 条
[71]   Esomeprazole - A review of its use in the management of acid-related disorders [J].
Scott, LJ ;
Dunn, CJ ;
Mallarkey, G ;
Sharpe, M .
DRUGS, 2002, 62 (10) :1503-1538
[72]   Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage [J].
Singh, G ;
Triadafilopoulos, G .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (10) :1210-1217
[73]  
Singh G, 1998, J RHEUMATOL, V25, P8
[74]   Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults [J].
Solomon, DH ;
Schneeweiss, S ;
Glynn, RJ ;
Kiyota, Y ;
Levin, R ;
Mogun, H ;
Avorn, J .
CIRCULATION, 2004, 109 (17) :2068-2073
[75]  
Stillman MJ, 2007, GERIATRICS-US, V62, P26
[76]   Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization [J].
Sun, Shawn X. ;
Lee, Kwan Y. ;
Bertram, Carl T. ;
Goldstein, Jay L. .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (08) :1859-1866
[77]   Novel effects other than antisecretory action and off-label use of proton pump inhibitors [J].
Suzuki, H ;
Hibi, T .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (01) :59-67
[78]   Omeprazole attenuates oxygen-derived free radical production from human neutrophils [J].
Suzuki, M ;
Mori, M ;
Miura, S ;
Suematsu, M ;
Fukumura, D ;
Kimura, H ;
Ishii, H .
FREE RADICAL BIOLOGY AND MEDICINE, 1996, 21 (05) :727-731
[79]  
Szabó I, 2000, J PHYSIOL PHARMACOL, V51, P3
[80]   Cellular and molecular mechanisms of gastrointestinal ulcer healing [J].
Tarnawski, AS .
DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (Suppl 1) :S24-S33